Summary:
In patients with type 2 diabetes and chronic kidney disease (CKD), weekly semaglutide 1.0 mg for a median of 3.4 years significantly reduced the risk of major kidney events and death by 24%, slowed annual eGFR decline by 1.16 ml/min/1.73m², and lowered risks of death (20%) and cardiovascular events (18%) compared to placebo over the same duration, with fewer serious adverse events reported (49.6% vs. 53.8%).
| PICO | Description |
|---|---|
| Population | Adults with overweight or obesity and established cardiovascular disease, without diabetes. |
| Intervention | Once-weekly administration of semaglutide 2.4 mg. |
| Comparison | Placebo administered once weekly. |
| Outcome | Semaglutide significantly reduced the incidence of the composite kidney endpoint. Improvement in eGFR at 104 weeks was observed, with a more pronounced benefit in participants with baseline eGFR <60 ml/min/1.73 m2. |
Source: Colhoun, Helen M, et al. “Long-term Kidney Outcomes of Semaglutide in Obesity and Cardiovascular Disease in the SELECT Trial.” Nat Med, 2024 Jul; 30(7): 2058-2066. Read article here.
